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Abstract Low levels of high-density lipoprotein (HDL)-choles-
terol represent an independent cardiovascular risk factor and,
besides reduced physical activity, mechanisms leading to de-
creased HDL-cholesterol levels are not known. We aimed to
test the hypothesis, that adiponectin provides a missing link
between type 2 diabetes and low levels of HDL-cholesterol, in-
dependent from common metabolic risk factors. 523 patients
with type 2 diabetes were investigated for adiponectin serum
levels and parameters of lipid metabolism. Even after correction
for age, gender, BMI and fasting insulin concentration, serum
levels of adiponectin were highly signi¢cant (P6 0.0001) and
positively (regression analysis : r=0.86) associated with HDL-
cholesterol levels in type 2 diabetes. Conclusion: adiponectin
seems to predict HDL-cholesterol levels in patients with diabe-
tes mellitus type 2. Low levels of adiponectin are associated with
low levels of HDL-cholesterol independently from common met-
abolic risk factors and therefore represent an independent car-
diovascular risk factor in type 2 diabetes. Thus, adiponectin is a
potentially new drug target in the treatment of dyslipidaemia.
1 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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High-density lipoprotein (HDL)-cholesterol represents a
common and independent protective cardiovascular risk fac-
tor. Cardiovascular risk increases with decreasing levels of
HDL-cholesterol. While lipid lowering and antidiabetic drugs
such as statins, ¢brates, and PPARQ agonists as well as diet
alone have only marginal e¡ects on serum HDL-cholesterol
levels, physical activity is able to elevate e¡ectively HDL lev-
els. Since type 2 diabetes mellitus and obesity are associated
with low levels of HDL-cholesterol, a reduced physical activ-
ity has been regarded as the main mechanism standing behind
these low levels. Adiponectin [1^4] represents a newly discov-
ered adipocyte-speci¢c secretory protein. Its expression is
highly restricted to terminally di¡erentiated adipocytes. Adi-
ponectin is secreted into the plasma and represents a new
member of the recently described C1q/TNF molecular super-
family [3]. Since adiponectin is the only known adipocyte-spe-
ci¢c secretory protein in the human system, that is exclusively
and paradoxically decreased in obesity and type 2 diabetes
[1,4], we aimed to test the hypothesis that adiponectin might
in£uence HDL-cholesterol levels. For that purpose, a large
cohort of Caucasian patients with type 2 diabetes was inves-
tigated for serum adiponectin levels and parameters of lipid
metabolism. Human adiponectin serum concentrations were
measured by enzyme-linked immunosorbent assay (ELISA)
according to the protocol provided by the manufacturer (hu-
man adiponectin ELISA kit, Biocat, Heidelberg, Germany).
523 subjects, 296 males (56.6%) and 227 females (43.4%), were
included in the study. The main question was whether adi-
ponectin serum levels may predict HDL-cholesterol levels
after correction for age, gender, diabetes duration, HbA1c,
BMI and fasting insulin levels. As depictured in Fig. 1, we
were able to demonstrate a strong and highly signi¢cant
(P6 0.0001) positive correlation between adiponectin and
HDL-cholesterol levels (regression analysis : r=0.86). Adipo-
nectin serum levels were correlated to HDL-cholesterol even if
factors such as age, gender, BMI and fasting insulin concen-
tration were excluded.
Adiponectin seems to predict HDL-cholesterol levels in pa-
tients with diabetes mellitus type 2 independent from common
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Fig. 1. Adiponectin serum levels (Wg/ml) are highly signi¢cantly and
positively associated with HDL-cholesterol levels (mg/dl) indepen-
dent from age, gender, BMI and fasting insulin concentration
(P6 0.0001, regression analysis: r=0.86).
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metabolic factors. Low levels of adiponectin are associated
with low levels of HDL-cholesterol and might represent an
independent cardiovascular risk factor, whereas high levels
of adiponectin are associated with high levels of HDL-choles-
terol indicating a protective risk pro¢le. Adiponectin is there-
fore discussed as a potentially new drug target in the treat-
ment of dyslipidaemia and investigating the mechanism
standing behind the observed associations might provide the
basis for the development of ‘adiponectin agonists’ as HDL-
enhancing drugs.
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